PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2020-12-06

Date Title Company
06-Dec-2020 MAGROLIMAB DEMONSTRATES CLINICAL RESPONSES IN ONGOING PHASE 1B TRIAL OF PREVIOUSLY UNTREATED ACUTE MYELOID LEUKAEMIA PATIENTS Gilead Sciences, Inc.
06-Dec-2020 NEW FOUR-YEAR DATA SHOW LONG-TERM SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA TREATED WITH YESCARTA® (AXICABTAGENE CILOLEUCEL) IN ZUMA-1 TRIAL Kite, A Gilead Company
06-Dec-2020 YESCARTA® (AXICABTAGENE CILOLEUCEL) IS FIRST CAR T CELL THERAPY TO DEMONSTRATE HIGH RESPONSE RATES AND DURABLE CLINICAL BENEFIT IN A PIVOTAL INDOLENT NON-HODGKIN LYMPHOMA STUDY Kite, A Gilead Company
06-Dec-2020 CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting CTI BioPharma Corp.
06-Dec-2020 CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting CTI BioPharma Corp.
06-Dec-2020 Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD Syndax Pharmaceuticals, Inc.
06-Dec-2020 Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD Syndax Pharmaceuticals, Inc.
06-Dec-2020 CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition CARsgen Therapeutics Co. Ltd.
06-Dec-2020 CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition CARsgen Therapeutics Co. Ltd.